Oncology market in USA

pipeline, asthma, breast cancer, cancer, cervical cancer, chemotherapy, cns, copd, cox 2 inhibitor, diabetic, generics, neuropathic pain, osteoporosis, vaccine, vaccines,

gsk update jp garnier chief executive officer note growth rates a comparable rate basis q3 financial summary sales rx 4 2 bn 1 cx 0 8 3 profit before taxes 5 eps pharma excludes total paxil & wellbutrin in us europe canada 12 reported excluding generics key drivers respiratory cns cv diabetes seretide 609m 20 lamictal 172m 29 avandia 284m 31 anti viral valtrex 147m 27 coreg 110m q304 global and cer pipeline building the 2001 2004 50 82 32 38 15 phase iii reg ii i ples vaccines 113 147 nces 41 22 45 boniva entereg first once monthly oral bisphosphonate for osteoporosis 3bn market mid teens product management of post operative ileus million surgeries also development obd chronic constipation upcoming launches requip rls vesicare drug approved treatment restless leg syndrome target population 7 patients treats all symptoms over active bladder with low incidence dry mouth 1bn